bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair

PUBLISHED ON March 12, 2019

San Antonio, TX (March 12, 2019)  bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics and therapeutics, including CyPath® Lung.

read more

bioAffinity Technologies Selected as Finalist for Cancer Innovation Award

PUBLISHED ON March 6, 2019

San Antonio, TX (March 6, 2019) Healthcare innovators Lyfebulb and Helsinn selected, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation Award recognizes groundbreaking work to advance the prevention and management of cancer.

read more

bioAffinity Technologies Announces Award of Canadian Patent

PUBLISHED ON February 5, 2019

SAN ANTONIO, TX (February 4, 2019) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early detection of cancer.

read more

South Texas Veterans Health Care System Joins Test Validation Trial of bioAffinity’s CyPath® Lung

PUBLISHED ON October 23, 2018

SAN ANTONIO, TX (October 23, 2018) bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is affiliated with the federal Department of Veterans Affairs (VA) health care system, will be a clinical collection site for the Company’s test validation trial of CyPath® Lung, a non-invasive test for the early detection of lung cancer.

read more

BioAffinity Licenses Lung Cancer Test to Precision Pathology Services

PUBLISHED ON October 12, 2018

360Dx (October 10, 2018) BioAffinity Technologies today said that it has inked a licensing agreement with Precision Pathology Services for the continued development and commercial sale of its CyPath Lung assay as a laboratory-developed test used for the diagnosis of early-stage lung cancer.

read more

bioAffinity Technologies is proud to play a part in the University of Texas Health video highlighting our impressive research collaboration to uncover the mechanisms of cancer. The collaboration with the University of Texas, a leader in innovation, has led to exciting advancements that further the development and commercialization of our life-saving tests and treatments for cancer. In this video, you’ll see physicians, scientists, and bioAffinity Technologies CEO Maria Zannes discuss how medical breakthroughs are being commercialized and made available to those who need them, including more about how we’re moving forward with our CyPath® diagnostic tests and OncoSelect® therapeutics.